My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Repligen Corporation - Common Stock (NQ:RGEN)

149.48 +18.42 (+14.05%)

Streaming Delayed Price Updated: 2:05 PM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover ↗

February 06, 2023

Danaher is reportedly looking to add to its wheelhouse to compete with Thermo.

Via Investor's Business Daily

Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday ↗

January 30, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Shares of Repligen Rose This Week ↗

January 12, 2023

The company is coming off a solid third quarter and is getting noticed by analysts.

Via The Motley Fool

Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock ↗

December 07, 2022

Via Benzinga

Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact ↗

September 20, 2022

Via Benzinga

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says ↗

August 12, 2022

Via Benzinga

Expert Ratings for Repligen ↗

August 03, 2022

Analysts have provided the following ratings for Repligen (NASDAQ:RGEN) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Repligen: Q2 Earnings Insights ↗

August 02, 2022

Repligen (NASDAQ:RGEN) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Repligen Earnings Perspective: Return On Capital Employed ↗

November 09, 2022

Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) posted Q3 earnings of $40.41 million, an increase from Q2 of 18.96%. Sales dropped to $200.74 million, a 3.32% decrease between quarters.

Via Benzinga

Recap: Repligen Q3 Earnings ↗

November 01, 2022

Repligen (NASDAQ:RGEN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Repligen beat estimated earnings by...

Via Benzinga

Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday ↗

October 20, 2022

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...

Via Benzinga

Earnings Scheduled For November 1, 2022 ↗

November 01, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Via Benzinga

Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session ↗

October 19, 2022

Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share.

Via Benzinga

Abbott Laboratories, M&T Bank And Some Other Big Stocks Moving Lower On Wednesday ↗

October 19, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

MarketBeat: Week in Review 9/12 – 9/16

September 16, 2022

In volatile markets, rely on MarketBeat to keep you focused on your investment objectives. Here are some of our most popular articles from this week

Via MarketBeat

Topics Economy

Why Medical Products Maker Repligen May Be A Potential Buy

September 15, 2022

Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy?

Via MarketBeat

Top-Rated Stocks: Lantheus Stock Sees Composite Rating Climb To 96 ↗

September 01, 2022

Top-rated Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.

Via Investor's Business Daily

Golden Cross Appears Before Repligen Investors ↗

August 26, 2022

If history is any guide, there may be good fortune ahead for shares of Repligen (NASDAQ:RGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating ↗

August 16, 2022

On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before.

Via Investor's Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

Uber, Lyft And Some Other Big Stocks Recording Gains On Tuesday ↗

August 03, 2022

U.S. stocks closed lower on Tuesday, with the Dow Jones dropping more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday ↗

August 03, 2022

Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks.

Via Benzinga

Why Applied DNA Sciences Is Trading Higher By 166%, Here Are 75 Stocks Moving In Tuesday's Mid-Day Session ↗

August 02, 2022

Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD Digital.

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

Silk Road Medical Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

July 22, 2022

Silk Road Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 90.

Via Investor's Business Daily

Tesla, Danaher And Some Other Big Gainers From Yesterday ↗

July 22, 2022

U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.